(Q39150740)

9 September 2017

Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway (English)

1 reference

9 September 2017

hepatocellular carcinoma

1 reference

Xiao-Fang Dai

1

1 reference

9 September 2017

Jie Ding

2

1 reference

9 September 2017

Rui-Guang Zhang

3

1 reference

9 September 2017

Jing-Hua Ren

4

1 reference

9 September 2017

C-M Charlie Ma

5

1 reference

9 September 2017

Gang Wu

6

1 reference

9 September 2017

31 May 2013

1 reference

International Journal of Radiation Biology

9 September 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

9 September 2017

89

1 reference

9 September 2017

9

1 reference

9 September 2017

724-731

1 reference

RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo

9 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Review article: the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Radiosensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

[Sorafenib and radiotherapy association for hepatocellular carcinoma].

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Mitogen-activated protein kinases in hepatocellular carcinoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Characteristics of gamma-H2AX foci at DNA double-strand breaks sites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Current management strategy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Pathways of DNA double-strand break repair during the mammalian cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Sorafenib and radiation: a promising combination in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Conformal radiotherapy for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

Targeted therapy of hepatocellular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09553002.2013.791405

10.3109/09553002.2013.791405

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference